Why PPIs Are Not a Good Option in Atrophic Gastritis
Proton pump inhibitors are contraindicated or unnecessary in atrophic gastritis because these patients already have severely reduced or absent gastric acid secretion due to parietal cell loss, making acid suppression both physiologically inappropriate and potentially harmful.
The Core Pathophysiologic Problem
In atrophic gastritis, particularly corpus-predominant disease, the gastric mucosa has lost its acid-producing parietal cells. Administering PPIs to suppress acid production in a stomach that already produces little to no acid is fundamentally illogical 1, 2. This is analogous to treating hypothyroidism with antithyroid medication.
Key Evidence Points:
- Gastrin levels fail to rise appropriately with PPI therapy in atrophic gastritis patients, indicating absent gastric acid negative feedback—because there's no acid to suppress 3
- In a real-world study of 1,015 dyspeptic patients on PPIs, 41.1% showed low gastrin response (G17 1-7) and 20.4% showed absent response (G17 <1), regardless of PPI dosage, indicating the medication was physiologically ineffective 3
- Only 34.9% of patients showed adequate therapeutic response to PPIs overall, reaching just 66.7% even at the highest doses 3
Specific Harms of PPI Use in Atrophic Gastritis
1. Worsening of Corpus Atrophy
Long-term PPI use in Helicobacter pylori-positive patients with atrophic gastritis accelerates the progression of corpus atrophic changes 4, 5. The mechanism involves:
- Bacterial overgrowth under hypochlorhydric conditions
- Production of potentially carcinogenic N-nitrosocompounds by nitrosating organisms
- Enhanced oxyntic gastritis 5
2. Increased Gastric Cancer Risk
The combination of PPIs and atrophic gastritis creates a perfect storm for gastric carcinogenesis 4:
- Hypergastrinemia induced by PPIs may promote gastric cancer development
- Bacterial overgrowth produces carcinogenic compounds
- Bile acid interactions under altered pH conditions contribute to carcinogenicity
3. Unnecessary Medication Burden
PPIs provide no benefit when there's no acid to suppress, yet expose patients to 6:
- Pill burden
- Medication costs
- Potential adverse effects (pneumonia, hip fracture, C. difficile infection, micronutrient deficiencies) 6, 7
The H. pylori Eradication Exception
The ONLY appropriate use of PPIs in atrophic gastritis is as part of H. pylori eradication regimens—and even this is questionable.
Recent evidence challenges this traditional approach:
- A 2025 study demonstrated 90.1% overall eradication rates WITHOUT PPIs in corpus atrophic gastritis patients 1
- Single-pill bismuth therapy without PPIs achieved 97.7% eradication versus 78.6% with amoxicillin-based therapy without PPIs 1
- Only mild, self-limiting adverse events occurred (4 patients with bismuth therapy, 2 with amoxicillin therapy) 1
The rationale: In corpus atrophic gastritis with impaired acid secretion, the acid-suppressing effect of PPIs provides no additional benefit for antibiotic efficacy 1, 2.
Clinical Algorithm for Management
Step 1: Confirm Diagnosis
- Serum pepsinogen I <30 mcg/L strongly suggests corpus atrophic gastritis
- For PG-I 30-50 mcg/L ("grey zone"): perform PPI challenge test—if PG-I increases <30% after 1 week of esomeprazole 40mg daily, atrophic gastritis is confirmed (95% PPV, 96% specificity) 8
Step 2: Assess H. pylori Status
- Test all atrophic gastritis patients for H. pylori 2, 9
- Immunoblotting detects past exposure in virtually all AG patients 2
Step 3: Treatment Decision Tree
If H. pylori positive:
- First choice: Bismuth-based quadruple therapy WITHOUT PPIs (97.7% eradication rate) 1
- Alternative: Amoxicillin-based therapy WITHOUT PPIs (78.6% eradication rate) 1
- Traditional PPI-containing regimens may be used but offer no proven advantage in this population 2
If H. pylori negative:
- Discontinue any existing PPI therapy immediately 6
- Atrophic gastritis is NOT an indication for chronic PPI use per AGA guidelines 6
Step 4: Surveillance
- Endoscopic surveillance per OLGA staging system 9
- Monitor for progression to intestinal metaplasia and dysplasia
- Lifestyle modifications and health education 9
Critical Pitfall to Avoid
The most common error is continuing PPIs in atrophic gastritis patients "because they've always been on them." This represents inappropriate prescribing that:
- Provides zero therapeutic benefit (no acid to suppress)
- Potentially accelerates gastric cancer risk
- Exposes patients to unnecessary adverse effects
- Wastes healthcare resources
Per AGA Best Practice Advice: All patients taking PPIs should have regular review of ongoing indications, and those without definitive indication should be considered for de-prescribing 6. Atrophic gastritis is explicitly NOT listed as an indication for long-term PPI use in the AGA's comprehensive indication table 6.